Pressure Is On Cannabinoid Drug Developer GW As Sativex Fails First Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
GW Pharmaceuticals – a leader in development of cannabis plant-derived drugs – suffers setback with failure in its first Phase III study in cancer pain; results of two more studies are yet to be reported.